stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / VRTX / Free Cash Flow

Vertex Pharmaceuticals Incorporated Free Cash Flow 2008–2025

Vertex Pharmaceuticals Incorporated (VRTX) annual free cash flow by fiscal year, computed from SEC filings.

Fiscal yearFree Cash FlowChange (YoY)
FY 2025$3.19B+504.1%
FY 2024$-790.30M-123.7%
FY 2023$3.34B-15.0%
FY 2022$3.93B+63.0%
FY 2021$2.41B-19.5%
FY 2020$2.99B+100.4%
FY 2019$1.49B+27.2%
FY 2018$1.17B+57.6%
FY 2017$745.52M+315.2%
FY 2016$179.54M+143.7%
FY 2015$-410.73M+34.2%
FY 2014$-624.31M-457.1%
FY 2013$-112.06M-157.0%
FY 2012$196.70M+80.2%
FY 2011$109.14M+116.2%
FY 2010$-673.50M-49.3%
FY 2009$-451.08M-74.4%
FY 2008$-258.66M

Source: Vertex Pharmaceuticals Incorporated SEC filings — cash flow statement (10-K). Refreshed nightly.

See the full picture for Vertex Pharmaceuticals Incorporated

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Vertex Pharmaceuticals Incorporated — frequently asked questions

What is Vertex Pharmaceuticals Incorporated's free cash flow?

Vertex Pharmaceuticals Incorporated (VRTX) reported free cash flow of $3.19B for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Vertex Pharmaceuticals Incorporated's official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.

More VRTX financial history

Full VRTX fundamentals page → · All 1,500+ companies →